Cost-effectiveness requirements vary sharply across the Gulf — Saudi Arabia's SFDA framework, DHA health economics review in Dubai, and informal economic arguments for formulary committees in Kuwait, Qatar, Bahrain, and Oman are genuinely different processes. This page compares them side by side; for the full Saudi-specific methodology, see cost-effectiveness analysis Saudi Arabia.
SFDA's Economic Evaluation System, mandatory from July 2025, classifies cost-utility analysis as a "Full Economic Study" with published guidance — the most current, publicly documented HTA-adjacent framework in the GCC. See cost-effectiveness analysis Saudi Arabia for the full requirements.
No GCC country publishes a formal willingness-to-pay threshold. A research-derived Saudi estimate of roughly SAR 50,000–75,000/QALY and informal UAE benchmarks of $40,000–$80,000/QALY guide what passes scrutiny, but neither is official government policy.
Reviewers across Saudi Arabia and the UAE increasingly challenge models built on Western utility values and cost data. Saudi and UAE-specific inputs — derived from NHIC data, KFSH&RC cost studies, and NUPCO drug prices — are now the credibility baseline.
Cost-effectiveness analysis (CEA) is the standard methodology used by health technology assessment (HTA) bodies and payers to evaluate whether the health benefits of a new medicine justify its cost compared to existing treatment alternatives. The core metric is the incremental cost-effectiveness ratio (ICER): the additional cost of a new treatment divided by the additional health benefits it generates, expressed as cost per quality-adjusted life year (QALY) gained.
A QALY is a composite measure combining length of life and quality of life. One QALY equals one year of life in perfect health; a year of life in a health state scored at 0.7 utility contributes 0.7 QALYs. Utility values for different disease states are typically derived from preference-based instruments such as the EQ-5D-5L, administered to patient populations and valued using a country-specific social tariff. For GCC submissions, utility values from Arab populations — increasingly available from published studies in Saudi Arabia, UAE, and Egypt — are preferred over direct transfers from UK or US tariffs.
The ICER is compared against the payer's willingness-to-pay (WTP) threshold. If the ICER falls below the threshold, the treatment is considered cost-effective from the payer's perspective. In GCC markets, where no formal published WTP threshold exists, the informal benchmarks observed in practice guide this judgement — making the absolute ICER value, the clinical context, and the burden of disease arguments all important components of the value narrative.
The GCC healthcare financing landscape is heterogeneous and determines which payer perspective an economic model should adopt. Understanding the financing model of each target market is essential before designing a cost-effectiveness analysis.
Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman operate predominantly government-funded healthcare systems where the Ministry of Health provides free care to citizens and subsidised care to residents. In Saudi Arabia, the MOH manages a majority of hospital beds and funds medicines through centralised NUPCO procurement. This creates a single-payer dynamic where the MOH perspective is the dominant analytical lens: the CEA should model costs from the MOH healthcare budget perspective, and the budget impact model should quantify the net annual cost to the MOH sector. In Kuwait, the Ministry of Health Central Pharmacy procures medicines for all public facilities — a similar dynamic applies. In Qatar, the Supreme Council of Health (now MoPH) and Hamad Medical Corporation jointly determine formulary access; the payer perspective is effectively the HMC institutional budget.
Dubai introduced mandatory health insurance for all residents in 2006 (fully implemented by 2016), and Abu Dhabi has operated mandatory insurance since 2006 for expatriates and 2008 for citizens. This creates a multi-payer environment where insurers (Daman, AXA Gulf, MSH, and over 30 others regulated by DHA or DOH) bear the cost of medicines prescribed under insurance coverage. The DHA's Essential Medicine List (EML) governs what is covered; the DHA Health Economics Department evaluates high-cost medicines before EML inclusion. From a CEA perspective, the UAE payer is fragmented: for DHA submissions, the health economic model should reflect the cost to the insured population's pooled healthcare budget, using UAE-specific drug prices (DHA price schedule), hospital costs, and UAE utility tariffs where available. The DOH in Abu Dhabi has parallel requirements for the Thiqa benefit plan covering UAE nationals.
No GCC country has formally published a WTP threshold per QALY. All thresholds that practitioners reference are informal benchmarks or research-derived estimates, not government policy. The following ranges represent the current professional consensus:
Saudi Arabia operates the GCC's most publicly documented economic-evaluation framework, anchored by SFDA's Economic Evaluation Studies Guideline (published July 2024) and Pharmacoeconomic Submission Portal Manual (January 2025), with the economic-evaluation requirement mandatory from 1 July 2025. Health technology assessment operates as a national HTA function within SFDA, and the country's formal HTA framework continues to be formalized — sponsors should expect the review pathway to keep evolving rather than treat today's process as fixed.
SFDA's framework classifies cost-utility analysis (cost-effectiveness expressed as cost per QALY) as a "Full Economic Study," distinct from the lighter "Partial Economic Study" tier covering budget impact and cost-minimisation analysis. Where a Full Economic Study is required, SFDA expects a budget impact analysis as a mandatory companion document, and comparator selection consistent with SFDA's external reference-pricing framework. The full methodology — evidence tiers, comparator selection, sensitivity-analysis expectations, and the current threshold discussion — is covered in depth on cost-effectiveness analysis Saudi Arabia.
In addition to the SFDA registration process, NUPCO formulary submissions expect an economic argument as part of the negotiated tender pricing process. A model demonstrating cost-effectiveness at the proposed NUPCO price strengthens the sponsor's pricing position, independent of whether SFDA's Full Economic Study tier formally applies to the product.
The choice of model structure depends on the disease area, the nature of the clinical data, and the time horizon required. BioNixus builds three primary model architectures for GCC submissions:
Appropriate for acute, short-duration conditions where patients progress through a defined sequence of events within a time horizon of weeks to months — for example, a course of antibiotics for community-acquired pneumonia, an acute coronary syndrome intervention, or a surgical procedure. The decision tree structure maps clinical pathways, assigns probabilities to each branch, and applies costs and utility values to calculate expected ICER. GCC-specific applications include acute infectious disease treatment and episodic dermatological therapies.
The most widely used model structure for chronic conditions in GCC HTA submissions. A Markov model defines a set of mutually exclusive health states (e.g., controlled diabetes, uncontrolled diabetes, diabetic nephropathy, dialysis, dead) and models patient transitions between states over annual or quarterly cycles throughout a lifetime horizon. State-specific costs and utility values determine the cumulative ICER. Markov models are the standard for type 2 diabetes (using the UKPDS or IMS CORE Diabetes Model framework, adapted for GCC inputs), cardiovascular disease, chronic respiratory conditions, and oncology in early and late-stage disease. Saudi and UAE reviewers are familiar with Markov methodology and expect transparent documentation of transition probability sources, with local GCC literature cited where available.
Standard for oncology cost-effectiveness analyses where clinical evidence is based on progression-free survival (PFS) and overall survival (OS) curves from pivotal RCTs. The partitioned survival model divides the modelled cohort into three health state partitions — progression-free, progressed, and dead — based on fitted survival curves, and applies state-specific costs and utilities. For oncology submissions, BioNixus fits standard parametric curves (exponential, Weibull, log-logistic, log-normal, Gompertz) to PFS and OS Kaplan-Meier data, selects the best-fitting extrapolation with clinical validation from GCC oncology experts, and conducts sensitivity analyses across plausible survival assumptions.
Discrete event simulation (DES) models simulate individual patient pathways through disease progression, capturing heterogeneity in patient characteristics and allowing time-dependent transitions without the Markov memoryless assumption. DES models are appropriate for complex diseases with highly individual trajectories — such as multiple myeloma, some rare diseases, or conditions where prior treatment history materially affects future outcomes. DES models require more computational resources and longer development times than Markov models and are used selectively where model complexity is scientifically justified.
The methodological challenge that most distinguishes GCC economic modelling from European or US modelling is the sourcing of locally relevant input data. BioNixus has developed a structured data sourcing approach for each input category:
GCC-specific event rates are increasingly available in the published literature — the Saudi Arabia Diabetes Study (SADS), the Gulf RACE registry (acute coronary syndromes), and the Saudi National Cancer Registry provide locally relevant baseline event rates for major disease areas. When GCC-specific rates are unavailable, systematic literature review identifies the closest available populations (Arab, Middle Eastern, or South Asian if applicable) and a formal transferability assessment documents the extent and direction of potential bias.
Utility values derived from Arab populations are now available for type 2 diabetes, cardiovascular disease, chronic kidney disease, and several oncology indications. BioNixus maintains a curated database of published utility values from GCC and wider Arab population studies. For indications without published GCC utility data, BioNixus can generate primary utility data through patient EQ-5D-5L surveys in UAE or KSA hospital settings as part of a prospective study design.
Saudi Arabia unit costs are derived from: NUPCO published drug price lists (updated quarterly and publicly available); KFSH&RC cost studies where published; MOH fee schedules for outpatient consultations, inpatient bed-days, and procedures; and primary expert interviews with health economists and finance staff at reference hospitals. UAE costs are derived from: DHA schedule of benefits and procedure tariffs; Daman insurance reimbursement schedules; and published cost analyses from UAE teaching hospitals. All costs are expressed in USD for modelling convenience and converted back to SAR or AED for the final submission outputs.
Population inputs for budget impact models — disease prevalence, incident cases per year, eligible patient population — are derived from the Saudi NHIC Statistical Yearbook, MOH annual health reports, published GCC epidemiology surveys, and primary research where aggregate data is insufficient. For rare diseases, patient registry data or specialist physician surveys may be required to estimate treatable population sizes.
Budget impact models (BIMs) are required alongside cost-effectiveness analyses for SFDA Full Economic Study submissions and are increasingly requested for Abu Dhabi DOH Essential Drug List reviews and NUPCO tender negotiations. The BIM structure for GCC submissions includes:
For full details of BioNixus budget impact modelling capabilities, see budget impact model Saudi Arabia. For the broader HEOR strategy context, see HEOR consulting Saudi Arabia.
GCC economic modellers face three methodological challenges that differ substantively from European modelling practice:
Transferability of utility values: Health state utility values from UK or US preference studies are not directly applicable to Arab populations, where cultural, religious, and social factors may result in different EQ-5D responses for equivalent health states. BioNixus always conducts a formal transferability assessment when using non-Arab utility values, documenting the direction and likely magnitude of the transferability assumption, and where possible substituting published Arab utility data or commissioning primary utility collection.
Local unit cost availability: GCC healthcare cost data is far less standardised and publicly available than NHS reference cost databases or US Medicare fee schedules. BioNixus maintains a proprietary GCC healthcare cost database built from published cost studies, public price schedules, and primary expert elicitation, which reduces the cost collection phase for each new model and ensures consistency across projects.
Life expectancy and mortality data: Saudi and UAE general population life tables are published by WHO and the respective statistical authorities and are suitable for background mortality inputs. However, disease-specific mortality adjustment factors from GCC populations (e.g., cardiovascular mortality multipliers for diabetic patients in Saudi Arabia) are less consistently available and require careful literature review or assumption documentation in the modelling report.
BioNixus provides end-to-end health economic modelling and dossier support for pharmaceutical companies pursuing GCC market access. Our service covers:
Related pages: cost-effectiveness analysis Saudi Arabia, HEOR consulting Saudi Arabia, budget impact model Saudi Arabia, real world evidence GCC, Saudi payer market access research, UAE pricing and reimbursement strategy.
Not for every listing, but the threshold for when one is expected has narrowed since SFDA's Economic Evaluation System became mandatory in July 2025. SFDA classifies cost-utility analysis (cost-effectiveness expressed as cost per QALY) as a "Full Economic Study," required for products — typically chronic-disease, oncology, and specialty therapies — where comparative effectiveness against standard of care is a material consideration. Products with a lighter cost or clinical profile may only require the smaller "Partial Economic Study" tier (budget impact analysis). Teams that submit without the required tier risk a delayed or conditional listing, or additional review queries from NUPCO's centralised tender process. For the full Saudi-specific methodology and evidence-tier guidance, see cost-effectiveness analysis Saudi Arabia.
No GCC country has published a formal, fixed willingness-to-pay (WTP) threshold per QALY. Saudi Arabia has the most developed public discussion of a research-derived threshold — an estimate of roughly SAR 50,000 to 75,000 per QALY (about 58%–86% of GDP per capita) drawn from published health-economics literature, not a government policy document; see cost-effectiveness analysis Saudi Arabia for the full framing. For the UAE (DHA/Dubai insurer perspective), informal benchmarks in the $40,000–$80,000 per QALY range (roughly AED 150,000–300,000) are observed in DHA health economics reviews, reflecting higher per-capita healthcare spending. Qatar's high GDP per capita suggests potential acceptance of higher ICERs for serious conditions, but no formal HTA body or threshold exists; HMC formulary decisions are made by a clinical committee with budgetary awareness rather than a systematic QALY calculation. Kuwait, Bahrain, and Oman have no formal HTA body, and formulary decisions are driven primarily by clinical guidelines, price relative to standard of care, and budget impact rather than a cost-per-QALY calculation.
A cost-effectiveness or budget impact model for a GCC submission requires five categories of data inputs, and sourcing locally relevant versions of each is the primary methodological challenge. First, transition probabilities or clinical event rates: derived from RCT data where available, supplemented by published observational studies; for GCC-specific transitions (e.g., diabetes complications rates in Arab populations), peer-reviewed literature from the Gulf region or MENA, or local RWD studies, should replace Western clinical inputs where material differences exist. Second, utility values (health state values for QALYs): ideally generated from studies in Arab populations using validated preference-based instruments such as EQ-5D-5L; published utility studies from KSA, UAE, or Egypt now exist for major chronic conditions including diabetes, cardiovascular disease, and oncology. Third, unit costs: GCC-specific resource use costs are the hardest input to standardise. BioNixus uses KFSH&RC (King Faisal Specialist Hospital and Research Centre) published cost studies, NUPCO drug price lists, MOH fee schedules, and primary cost collection from clinical expert interviews to build Saudi-specific cost databases. UAE unit costs can be derived from DHA procedure tariffs and Daman insurance reimbursement schedules. Fourth, population epidemiology: disease prevalence and incidence for model cohort sizing, drawn from NHIC statistical yearbooks, published Saudi epidemiology literature, and regional WHO data. Fifth, discount rates: current SFDA and NCEHTA guidance should be confirmed at the time of submission rather than assumed fixed, since technical reference-case parameters are part of a guideline that continues to be updated.
Cost-effectiveness analysis (CEA) and budget impact modelling (BIM) address fundamentally different questions and serve different decision-making purposes, though both are typically required for a complete GCC market access submission. A cost-effectiveness analysis asks whether the health outcomes gained from a new intervention are worth the additional cost — the answer is expressed as the incremental cost-effectiveness ratio (ICER), measured in cost per quality-adjusted life year (QALY) gained. The CEA adopts a societal or healthcare system perspective and models outcomes over a long time horizon (often lifetime) to fully capture the value of durable clinical benefits. A budget impact model, by contrast, asks a purely financial question: how much will it cost the payer to fund this drug over the next 3–5 years given realistic uptake assumptions? The BIM does not require a QALY calculation; it models drug acquisition costs, offset savings from displaced treatments or avoided complications, and net budget impact per year. SFDA expects a budget impact model as a mandatory companion to any submission requiring a Full Economic Study. The Abu Dhabi DOH also requires a BIM for high-cost medicines included in the DOH Essential Drug List review. In BioNixus practice, CEA and BIM are developed in parallel from a shared dataset, with the CEA informing the value argument and the BIM quantifying affordability and managing payer risk through managed entry agreement design.
Western models can serve as a starting point — and many Saudi and UAE submissions do begin from a model originally built for EMA or NICE — but direct transfer without adaptation is rarely sufficient to satisfy GCC HTA reviewers. The key adaptation requirements are: (1) replace Western utility values with locally validated or published GCC/Arab population utility data where available, since health state preferences can differ materially between patient populations; (2) replace Western unit costs with Saudi or UAE-specific drug prices (NUPCO list prices), hospital stay costs, and procedure costs — Western DRG-based costs are systematically different from Gulf healthcare costing structures; (3) adjust clinical event rates and natural history assumptions for GCC-specific epidemiological context (e.g., diabetes complication rates in Saudi Arabia are different from UK rates due to differences in baseline glycaemic control, obesity prevalence, and comorbidity); (4) resize the model population using Saudi or UAE epidemiological data rather than NHS or US census data; (5) confirm and apply the discount rate, time horizon, and sensitivity-analysis requirements specified in the current SFDA or DHA guidance at the time of submission, rather than a fixed assumption carried over from a prior engagement. A full GCC adaptation of a well-documented NICE-format model typically requires several weeks of dedicated modelling effort and is included within BioNixus's CEA/BIM development scope.
Review timelines vary depending on submission complexity, the completeness of the economic evidence package, and how many rounds of clarification questions a review generates — BioNixus scopes the expected calendar against SFDA's current published guidance for each engagement rather than a fixed industry-wide figure. As a general planning principle, sponsors should begin HTA preparation well ahead of the desired listing date to allow time for iterative model refinement, dossier writing, and response to clarification questions. BioNixus supports the full pre-submission phase — economic model development, systematic literature review, dossier writing, and response to SFDA clarification questions — and maps a realistic submission calendar during scoping rather than assuming a generic timeline applies. See cost-effectiveness analysis Saudi Arabia for the current SFDA framework this timeline sits within.